

Appendix 4E

Preliminary Final Report to the Australian Securities Exchange

Name of Entity	Tissue Therapies Limited
ABN	45 101 955 088
Financial Year Ended	30 June 2011
Previous Corresponding Reporting Period	30 June 2010

Results for Announcement to the Market

	\$	\$ Movement over previous corresponding period	Percentage increase /(decrease) over previous corresponding period
Revenue from ordinary activities	452,610	71,905	18.88%
Profit / (loss) from ordinary activities after tax attributable to members	(5,340,548)	(1,854,149)	(53.18%)
Net profit / (loss) for the period attributable to members	(5,340,548)	(1,854,149)	(53.18%)

Dividends (distributions)		Franked amount per security
Final Dividend	-	-
Interim Dividend	-	-
Record date for determining entitlements to the dividends (if any)		-

Brief explanation of any of the figures reported above necessary to enable the figures to be understood:
Refer to the accompanying director's report, financial statements and notes.

Tissue Therapies Limited – Appendix 4E Preliminary Final Report

Ratios

	Current period	Previous corresponding period
Profit/(loss) before tax / revenue Profit (loss) from ordinary activities before tax as a percentage of revenue	(1,247.34%)	(915.80%)
Profit after tax / equity interests Net profit (loss) from ordinary activities after tax attributable to members as a percentage of equity (similarly attributable) at the end of the period	(31.35%)	(43.90%)

NTA Backing

	Current Period	Previous corresponding period
Net tangible asset backing per ordinary security	9.89cents	5.50cents

Commentary on the Results for the Period

Refer to the accompanying director's report, financial statements and notes.

Audit/Review Status

This report is based on accounts to which one of the following applies: (Tick one)			
The accounts have been have been audited and the audit report contains no qualifications	X	The accounts have been subject to review	
The accounts are in the process of being audited or subject to review		The accounts have not yet been audited or reviewed	

Financial Statements

Refer to the accompanying director's report, financial statements and notes.

Annual General Meeting

The company's 2011 annual general meeting is scheduled for 28 November 2011.

By Order of the Board



Roger Clarke
Chairman
10 August 2011